BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Rox Medical Inc. Enrolls First Patients in Ireland for CONTROL-HTN Hypertension Trial at Beaumont and Mater Private Hospitals


3/5/2013 9:40:50 AM

SAN CLEMENTE, Calif., March 4, 2013 /PRNewswire/ -- ROX Medical announced enrollment of the first two Irish patients in the CONTROL-HTN randomized controlled trial of the ROX FLOW procedure for the treatment of resistant hypertension. Both patients were evaluated by hypertension specialists, Professor Alice Stanton, M.D. of Beaumont Hospital and Eamon Dolan, M.D. of Connolly Hospital in Dublin. One of the two patients was randomized to receive the ROX FLOW procedure, which was performed by Joseph Galvin, M.D. at The Mater Private Hospital, Dublin, Ireland. The minimally invasive procedure was performed in the cardiac catheter lab in less than one hour. The ROX procedure is a reversible therapy option for the management of resistant hypertension and may offer an alternative and/or concomitant therapy option to another increasingly popular hypertension procedure, renal denervation.

(Logo: http://photos.prnewswire.com/prnh/20130304/LA70984LOGO)

ROX Medical's FLOW procedure is a minimally invasive, catheter procedure whereby a small nitinol coupler is inserted between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance, thereby holding the promise of a meaningful long-term reduction in hypertension. Uniquely, the FLOW procedure only involves the vascular structure, has an immediate effect; and is fully reversible.

"We congratulate the physicians at Beaumont, Connolly and Mater Private hospitals for their first successful enrollments in the CONTROL-HTN study", said ROX CEO Rodney Brenneman. "The ROX procedure is unique in providing a complimentary and/or alternative therapy option to the other major device approach, renal denervation", Brenneman said, "Device approaches are becoming accepted as important additional therapies physicians may employ for the thousands of uncontrolled hypertensive patients throughout the world".

The ROX FLOW procedure for hypertension is not approved for use in the U.S.

SOURCE ROX Medical



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES